46 related articles for article (PubMed ID: 12506182)
1. Dendritic cell-based vaccination in solid cancer.
Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Schueller G; Zontsich T; Benkoe T; Radelbauer K; Brostjan C; Jakesz R; Gnant M
J Clin Oncol; 2003 Jan; 21(1):135-42. PubMed ID: 12506182
[TBL] [Abstract][Full Text] [Related]
2. Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer.
Qi CJ; Ning YL; Han YS; Min HY; Ye H; Zhu YL; Qian KQ
Cancer Immunol Immunother; 2012 Sep; 61(9):1415-24. PubMed ID: 22290073
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer.
Iwashita Y; Tahara K; Goto S; Sasaki A; Kai S; Seike M; Chen CL; Kawano K; Kitano S
Cancer Immunol Immunother; 2003 Mar; 52(3):155-61. PubMed ID: 12649744
[TBL] [Abstract][Full Text] [Related]
4. Combining chemotherapy and autologous peptide-pulsed dendritic cells provides survival benefit in stage IV melanoma patients.
Eisendle K; Weinlich G; Ebner S; Forstner M; Reider D; Zelle-Rieser C; Tripp CH; Fritsch P; Stoitzner P; Romani N; Nguyen VA
J Dtsch Dermatol Ges; 2020 Nov; 18(11):1270-1277. PubMed ID: 33197129
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective.
Li Y; Xiang S; Pan W; Wang J; Zhan H; Liu S
Front Oncol; 2023; 13():1166860. PubMed ID: 37064113
[TBL] [Abstract][Full Text] [Related]
6. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
Del Rivero J; Donahue RN; Marté JL; Gramza AW; Bilusic M; Rauckhorst M; Cordes L; Merino MJ; Dahut WL; Schlom J; Gulley JL; Madan RA
Front Endocrinol (Lausanne); 2020; 11():490. PubMed ID: 32849281
[TBL] [Abstract][Full Text] [Related]
7. Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN
Kumar C; Bagga J; Chiliveru S; Kohli S; Bharadwaj A; Jain M; Inamdar S; Sharan B
Future Sci OA; 2019 Oct; 5(10):FSO435. PubMed ID: 31827897
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma.
Yang J; Hu S; Shangguan J; Eresen A; Li Y; Pan L; Ma Q; Velichko Y; Wang J; Hu C; Yaghmai V; Zhang Z
Am J Cancer Res; 2019; 9(11):2456-2468. PubMed ID: 31815046
[TBL] [Abstract][Full Text] [Related]
9. Potentiality of immunotherapy against hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
[TBL] [Abstract][Full Text] [Related]
10. Personalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignancies.
Barar J; Omidi Y
Bioimpacts; 2015; 5(2):65-9. PubMed ID: 26191499
[TBL] [Abstract][Full Text] [Related]
11. SpyLigase peptide-peptide ligation polymerizes affibodies to enhance magnetic cancer cell capture.
Fierer JO; Veggiani G; Howarth M
Proc Natl Acad Sci U S A; 2014 Apr; 111(13):E1176-81. PubMed ID: 24639550
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells fused with different pancreatic carcinoma cells induce different T-cell responses.
Andoh Y; Makino N; Yamakawa M
Onco Targets Ther; 2013; 6():29-40. PubMed ID: 23378772
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol loading and ultrastable protein interactions determine the level of tumor marker required for optimal isolation of cancer cells.
Jain J; Veggiani G; Howarth M
Cancer Res; 2013 Apr; 73(7):2310-21. PubMed ID: 23378340
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.
Tada F; Abe M; Hirooka M; Ikeda Y; Hiasa Y; Lee Y; Jung NC; Lee WB; Lee HS; Bae YS; Onji M
Int J Oncol; 2012 Nov; 41(5):1601-9. PubMed ID: 22971679
[TBL] [Abstract][Full Text] [Related]
15. Targeting and utilizing primary tumors as live vaccines: changing strategies.
Yang X; Mortenson ED; Fu YX
Cell Mol Immunol; 2012 Jan; 9(1):20-6. PubMed ID: 22101245
[TBL] [Abstract][Full Text] [Related]
16. Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
Cao M; Xu Y; Youn JI; Cabrera R; Zhang X; Gabrilovich D; Nelson DR; Liu C
Lab Invest; 2011 Apr; 91(4):598-608. PubMed ID: 21321535
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for liver tumors: present status and future prospects.
Matar P; Alaniz L; Rozados V; Aquino JB; Malvicini M; Atorrasagasti C; Gidekel M; Silva M; Scharovsky OG; Mazzolini G
J Biomed Sci; 2009 Mar; 16(1):30. PubMed ID: 19272130
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumors with LIGHT to generate metastasis-clearing immunity.
Yu P; Fu YX
Cytokine Growth Factor Rev; 2008; 19(3-4):285-94. PubMed ID: 18508404
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture.
Dubsky P; Hayden H; Sachet M; Bachleitner-Hofmann T; Hassler M; Pfragner R; Gnant M; Stift A; Friedl J
Cancer Immunol Immunother; 2008 Jun; 57(6):859-70. PubMed ID: 18030468
[TBL] [Abstract][Full Text] [Related]
20. An ex vivo readout for evaluation of dendritic cell-induced autologous cytotoxic T lymphocyte responses against esophageal cancer.
Milano F; Rygiel AM; Buttar N; Bergman JJ; Sondermeijer C; van Baal JW; ten Brinke A; Kapsenberg M; van Ham SM; Peppelenbosch MP; Krishnadath KK
Cancer Immunol Immunother; 2007 Dec; 56(12):1967-77. PubMed ID: 17564704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
